A case report: rapid progression of coronary atherosclerosis in a patient taking Targretin (Bexarotene)

Anti-neoplastic drugs have made major advancements in oncology, however they are not without cardiovascular consequences. We present a patient with cutaneous T-cell lymphoma receiving Targretin therapy who presented with accelerated atherosclerosis. His triglyceride level (TG) was greater than 1000 ...

Full description

Saved in:
Bibliographic Details
Published inCardio-oncology (London, England) Vol. 6; no. 1; p. 31
Main Authors DeAngelo, Sean, Mann, Kailyn I, Abdulbasit, Muhammad, Ahnert, Amy, Sundlöf, Deborah W
Format Journal Article
LanguageEnglish
Published England BioMed Central 14.12.2020
BMC
Subjects
Angina pectoris
Atherosclerosis
Atypical angina
Cardiac catheterization
Cardiology
Cardiovascular disease
Case reports
Coronary vessels
Cutaneous T-cell lymphoma
Drug dosages
Emergency medical care
Health care networks
Heart
Intubation
Ischemia
Lipids
Lymphoma
Pain
Patients
Primary hypertriglyceridemia
Risk factors
Short Communication
Targretin (Bexarotene)
Task forces
Triglycerides
Ultrasonic imaging
United Kingdom > UK
Lehigh Valley
United States > US
Targretin (Bexarotene)
Atypical angina
Primary hypertriglyceridemia
Atherosclerosis
Cutaneous T-cell lymphoma
Online AccessGet full text

Cover

More Information
Summary:Anti-neoplastic drugs have made major advancements in oncology, however they are not without cardiovascular consequences. We present a patient with cutaneous T-cell lymphoma receiving Targretin therapy who presented with accelerated atherosclerosis. His triglyceride level (TG) was greater than 1000 mg/dL, which rapidly improved with discontinuation of Targretin.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2057-3804
2057-3804
DOI:10.1186/s40959-020-00087-3